^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    NPX267

    i
    Other names: NPX267, NPX 267, NPX-267
    Company:
    NextPoint
    Drug class:
    KIR3DL3 inhibitor
    8ms
    A Study of NPX267 for Subjects With Solid Tumors Known to Express HHLA2/B7-H7 (clinicaltrials.gov)
    P1, N=131, Suspended, NextPoint Therapeutics, Inc. | Trial completion date: Jan 2026 --> Sep 2025 | Recruiting --> Suspended | Trial primary completion date: Jan 2026 --> Sep 2025
    Trial completion date • Trial suspension • Trial primary completion date
    |
    NPX267
    2years
    A Study of NPX267 for Subjects With Solid Tumors Known to Express HHLA-2 (clinicaltrials.gov)
    P1, N=131, Recruiting, NextPoint Therapeutics, Inc.
    Trial completion date • Trial primary completion date
    |
    HHLA2 (HERV-H LTR-Associating 2)
    |
    NPX267
    over2years
    A Study of NPX267 for Subjects With Solid Tumors Known to Express HHLA-2 (clinicaltrials.gov)
    P1, N=131, Recruiting, NextPoint Therapeutics, Inc. | Phase classification: P1a/1b --> P1
    Phase classification
    |
    HHLA2 (HERV-H LTR-Associating 2)
    |
    NPX267
    over2years
    A Phase 1a/1b, dose-escalation/dose-expansion study of NPX267 in subjects with solid tumors known to express HHLA2 (SITC 2023)
    4 Key eligibility criteria include histologic diagnosis of tumor types known to express HHLA2, refractory metastatic or locally advanced disease and the absence of autoimmune disease or history of colitis or pneumonitis. HHLA-2 expression will be assessed by immunohistochemistry from archival tissue and fresh biopsies to assess correlation with pharmacodynamic and clinical activity to determine the potential use of HHLA2 expression as a prospective selection marker.
    Clinical • P1 data • PD(L)-1 Biomarker • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • HHLA2 (HERV-H LTR-Associating 2)
    |
    PD-L1 expression • EGFR mutation
    |
    NPX267
    over2years
    A Study of NPX267 for Subjects With Solid Tumors Known to Express HHLA-2 (clinicaltrials.gov)
    P1a/1b, N=131, Recruiting, NextPoint Therapeutics, Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    HHLA2 (HERV-H LTR-Associating 2)
    |
    NPX267
    over2years
    A Study of NPX267 for Subjects With Solid Tumors Known to Express HHLA-2 (clinicaltrials.gov)
    P1a/1b, N=131, Not yet recruiting, NextPoint Therapeutics, Inc.
    New P1 trial
    |
    HHLA2 (HERV-H LTR-Associating 2)
    |
    NPX267
    over3years
    NPX267, a first-in-class monoclonal antibody targeting KIR3DL3, blocks HHLA2-mediated immunosuppression and potentiates T and NK cell-mediated antitumor immunity (SITC 2022)
    Conclusions Collectively, these data demonstrate that the KIR3DL3-HHLA2 pathway is a novel immune checkpoint axis that facilitates tumor escape by attenuating both innate and adaptive antitumor immune responses. NPX267, a first-in-class KIR3DL3 blocking antibody, potentiates anti-tumor immunity against HHLA2 + tumors and may represent a promising approach to treat certain cancers.
    PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • HHLA2 (HERV-H LTR-Associating 2) • KIR2DS2 (Killer Cell Immunoglobulin Like Receptor, Two Ig Domains And Short Cytoplasmic Tail 2)
    |
    PD-L1 expression
    |
    NPX267